March 2, 2020 / 12:33 PM / a month ago

BRIEF-Prevail Therapeutics Announces Investigational NDA Active For PR006

March 2 (Reuters) - Prevail Therapeutics Inc:

* PREVAIL THERAPEUTICS ANNOUNCES INVESTIGATIONAL NEW DRUG APPLICATION ACTIVE FOR PR006 FOR THE TREATMENT OF FRONTOTEMPORAL DEMENTIA WITH GRN MUTATION Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below